1.
A. Nosari, A. Tedeschi, F. Ricci, M. Montillo. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. haematol [Internet]. 2008Feb.1 [cited 2021Mar.1];93(2):e30-e31. Available from: https://haematologica.org/article/view/4768